IOD Breast Pathology Flashcards

1
Q

How do the causes of breast lumps vary to age?

A

Young-fibroadenoma and fibrocystic change more, cancer less

Old-cancer more, fibroadenoma and fibrocystic changes less

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the triple assessment?

A

• Clinical -history and examination
• Radiological (mammography, ultrasound)
• mammography (usually in older patients >35yr). identifies microcalcifications and densities.
• ultrasound (usually in younger patients <35y because their breast tissue is too dense for
mammography) good for distinguishing solid and cystic lesions, and it can guide a needle test.
• Pathological - a needle test: FNA and/or core biopsy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the reporting categories?

A
C1/B1- inadequate
C2/B2 benign
C3/B3 equivocal favour benign
C4/B4 equivocal favour malignant
C5/B5 malignant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Accuracy in MDT?

A

99%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Fibroadenoma?

A

Common benign breast tumour
frim painless mobile lump
well-circumscribed and has well-differentiated glands in CT stroma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Fibrocystic?

A

Minor aberrations/cysts and fibrosis in second half of cycle
pain, tenderness, lumps
25-45 yrs
analgesics and aspiration/excision

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Lifetime risk of breast cancer?

A

1 in 8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

more common in?

A

40-70 yrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

major risk fctors?

A

oestrogen exposure, Fh and alcohol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

oestrogen exposure?

A

female,age,obesity,early menarche,, late menopause,COC, HRT >10 yrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Family history?

A

BRCA 1 and 2-AD

TP53

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How many are familial?

A

5-10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Risk reducing surgery?

A

bilateral mastectomy and salpingo-oophorectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

alcohol?

A

risk increases by 10% for each drink

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Clinical features?

A
upper outer quadrant of breast
hard painless lump
nipple inversion and skin dimpling
ulceration/fungation
peau d'orange
nipple eczema
palpable axillary nodes
metastatic disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

MDT?

A

oncologist, radiologist, pathologist, endocrinologist, specialist nurses etc

17
Q

pathology?

A

Ductal-75%
Lobular-10-15%
Both present in terminal duct lobular unit

18
Q

DCIS?

A

Epithelial cells showing signs of malignancy are in the TDLU but have not invaded past the basement membrane

19
Q

IDC?

A

Tumour cells invaded past the basement membrane into surrounding tissue and has potential to mets

20
Q

Features of DCIS?

A
carcinoma in situ
confined by BM
pre-cancerous
not always a mass
linked to microcalcifications-mammography
unifocal lesion on one area
surgically excised
21
Q

Features of IDC?

A

invasive growth and met potential

palpable breast mass

22
Q

Pagets disease?

A

DCIS cells in epidermis spreading to nipple and areola, causing inflammation

23
Q

Pagets features?

A

underlying invasive carcinoma
not all women with DCIS have it
not linked to P disease of bone

24
Q

Invasive lobular carcinoma

A

tumour cells infiltrating normal breast tissue linearly-loss of E cadherin catenin cell adhesion system

25
Other types?
tubular, cribiform, mucinous
26
Prognostic factors?
``` tumour stage-TNM grade-how aggressive histological subtype vascular invasion excision margins-prevents local recurrence oestrogen and her2 ```
27
oestrogen receptors and HER2?
ER+-lower grade and less aggressive-responsive to therapy HER2-oncogene coding for TKR HER2+-poor prognosis -response to herceptin
28
Sentinel LN?
First node draining a cancer if no cancer-highly likely no spread if cancer-chance of spread
29
Management?
+=axillary clearance | -=no removal
30
+ of sentinel node biopsy?
prognostic factor | no need for clearance and linked morbidities
31
Process of SNB?
Technetium 99m injected into tissue around tumour and nodes inspected for staining and uses gamma probe removed and examined by histopathologist
32
Screening?
Identify DCIS and small cancers earlier before signs develop 50-70 yrs every 3 yrs further assessment if needed
33
Further assessment?
imaging, exam, core biopsy